Being flexible about fine-tuning doses is key to finding the balance between tolerability and efficacy, “and consequently, for compliance,” he said.
Data collection for the study will end in 2018, with safety and efficacy data expected in 2019.
Conference Coverage
Hydroxyurea well tolerated in longitudinal European study
